Patents by Inventor Charles Robert Harrington
Charles Robert Harrington has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11951110Abstract: Described are methods of preparing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula: wherein: R1 and R9 are independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of HX1 and HX2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These methods are particularly useful for producing stable reduced forms, and with high purity. The stability and purity are especially relevant for pharmaceutical compositions for the treatment of disease. The compounds are useful for treatment of e.g. tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs.Type: GrantFiled: February 2, 2022Date of Patent: April 9, 2024Assignee: WisTa Laboratories Ltd.Inventors: Claude Michel Wischik, Janet Elizabeth Rickard, Charles Robert Harrington, David Horsley, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
-
Publication number: 20230266303Abstract: The present invention provides a system for the study of tau protein aggregation in neuronal cells in vitro which can be used to screen agents for therapeutic effectiveness against aggregates of tau protein or fragments thereof.Type: ApplicationFiled: July 9, 2021Publication date: August 24, 2023Inventors: Charles Robert HARRINGTON, Saskia Julie POLLACK, Karen Elizabeth MARSHALL, Louise Charlotte SERPELL, Claude Michel WISCHIK
-
Publication number: 20230257452Abstract: The invention relates to specific binding molecules, such as antibodies, directed to key epitopes of tau. The specific binding molecules of the invention find applications in diagnostics and therapeutics of tauopathies including Alzheimer's disease.Type: ApplicationFiled: July 9, 2021Publication date: August 17, 2023Inventors: Charles Robert HARRINGTON, Soumya PALLIYIL SOMAN, Andrew Justin Radcliffe PORTER, Claude Michel WISCHIK, Mohammad ARASTOO, Lewis Kirk PENNY, Richard LOFTHOUSE
-
Publication number: 20230031369Abstract: The present invention relates generally to methods of treatment of Alzheimer's Disease or Mild Cognitive Impairment which are adapted to avoid negative interactions between combinations of therapeutics. In particular there are disclosed such methods of treatment in which the order of therapeutics is actively controlled to mitigate homeostatic downregulation prior to administration of active, for example disease modifying, therapeutic agents. In certain embodiments therapy with symptomatic treatments (such as modifiers of the activity of acetylcholine or glutamate neurotransmitters) may subsequently be combined with the disease modifying or other active treatment. The invention also applies the findings in relation to homeostatic downregulation to novel methods of clinical trial design.Type: ApplicationFiled: June 30, 2020Publication date: February 2, 2023Applicant: WisTa Laboratories Ltd.Inventors: Gernot Riedel, Valeria Melis, Charles Robert Harrington, Jochen Klein, Grazyna Niewiadomska, Marta Steczkowska, Karima Schwab, Claude Michel Wischil
-
Publication number: 20220370470Abstract: The present invention relates generally to methods and materials for treating synaptopathies, based on the use of Leu-co-methylthioninium acid salts, which are disclosed herein to increase synaptophysin levels in various brain regions at therapeutically relevant doses both in animal models of neurodegenerative disease, and in normal animals.Type: ApplicationFiled: June 29, 2020Publication date: November 24, 2022Applicant: WisTa Laboratories Ltd.Inventors: Gernot Riedel, Charles Robert Harrington, Claude Michel Wischik
-
Publication number: 20220330594Abstract: The present invention relates generally to nootropic compositions comprising Leuco-methylthioninium acid salts and their uses for cognitive enhancement in normal (non-demented) individuals.Type: ApplicationFiled: June 29, 2020Publication date: October 20, 2022Applicant: WisTa Laboratories Ltd.Inventors: Gernot Riedel, Charles Robert Harrington, Jochen Klein, Karima Schwab, Claude Michel Wischik
-
Patent number: 11344558Abstract: Described are methods of preparing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula: wherein: R1 and R9 are independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of HX1 and HX2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These methods are particularly useful for producing stable reduced forms, and with high purity. The stability and purity are especially relevant for pharmaceutical compositions for the treatment of disease. The compounds are useful for treatment of e.g. tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs.Type: GrantFiled: October 30, 2015Date of Patent: May 31, 2022Assignee: WisTa Laboratories Ltd.Inventors: Claude Michel Wischik, Janet Elizabeth Rickard, Charles Robert Harrington, David Horsley, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
-
Publication number: 20220152038Abstract: Described are methods of prepraing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula: wherein: R1 and R9 are independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of HX1 and HX2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These methods are particularly usefull for producing stable reduced forms, and with high purity. The stability and purity are especially relevant for pharmaceutical compositions for the treatment of disease. The compounds are useful for treatment of e.g. tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs.Type: ApplicationFiled: February 2, 2022Publication date: May 19, 2022Applicant: WisTa Laboratories Ltd.Inventors: Claude Michel Wischik, Janet Elizabeth Rickard, Charles Robert Harrington, David Horsley, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
-
Publication number: 20220098161Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.Type: ApplicationFiled: October 12, 2021Publication date: March 31, 2022Applicant: WisTa Laboratories Ltd.Inventors: Colin Marshall, Scott Clunas, John Mervyn David Storey, James Peter Sinclair, Thomas Craven Baddeley, Ahtsham Ishaq, Michael Simpson, Craig Williamson, Barry Alan Wood, Claude Michel Wischik, Charles Robert Harrington, Janet Elizabeth Rickard, David Horsley, Yin Sze Loh, Karrar Ahmad Khan, Christopher Paul Larch
-
Patent number: 11180464Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.Type: GrantFiled: January 24, 2020Date of Patent: November 23, 2021Assignee: WisTa Laboratories Ltd.Inventors: Colin Marshall, Scott Clunas, John Mervyn David Storey, James Peter Sinclair, Thomas Craven Baddeley, Ahtsham Ishaq, Michael Simpson, Craig Williamson, Barry Alan Wood, Claude Michel Wischik, Charles Robert Harrington, Janet Elizabeth Rickard, David Horsley, Yin Sze Loh, Karrar Ahmad Khan, Christopher Paul Larch
-
Patent number: 10864216Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.Type: GrantFiled: March 5, 2018Date of Patent: December 15, 2020Assignee: WisTa Laboratories, Ltd.Inventors: Colin Marshall, Scott Clunas, John Mervyn David Storey, James Peter Sinclair, Thomas Craven Baddeley, Ahtsham Ishaq, Michael Simpson, Craig Williamson, Barry Alan Wood, Claude Michel Wischik, Charles Robert Harrington, Janet Elizabeth Rickard, David Horsley, Yin Sze Loh, Karrar Ahmad Khan, Christopher Paul Larch
-
Publication number: 20200246350Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.Type: ApplicationFiled: January 24, 2020Publication date: August 6, 2020Inventors: Colin Marshall, Scott Clunas, John Mervyn David Storey, James Peter Sinclair, Thomas Craven Baddeley, Ahtsham Ishaq, Michael Simpson, Craig Williamson, Barry Alan Wood, Claude Michel Wischik, Charles Robert Harrington, Janet Elizabeth Rickard, David Horsley, Yin Sze Loh, Karrar Ahmad Khan, Christopher Paul Larch
-
Patent number: 10399955Abstract: Described are a compound of formula (II) or (III): The compounds are effective in the treatment of disease, including a tauopathy condition or a disease of tau protein aggregation.Type: GrantFiled: December 8, 2016Date of Patent: September 3, 2019Assignee: WISTA LABORATORIES LTD.Inventors: Scott Clunas, John Mervyn David Storey, Janet Elizabeth Rickard, David Horsley, Charles Robert Harrington, Claude Michel Wischik
-
Publication number: 20190151329Abstract: Described are methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimised pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects.Type: ApplicationFiled: January 15, 2019Publication date: May 23, 2019Applicant: WisTa Laboratories Ltd.Inventors: Claude Michel WISCHIK, Damon Jude WISCHIK, John Mervyn David STOREY, Charles Robert HARRINGTON
-
Publication number: 20190046537Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.Type: ApplicationFiled: March 5, 2018Publication date: February 14, 2019Applicant: WisTa Laboratories Ltd.Inventors: Colin Marshall, Scott Clunas, John Mervyn David Storey, James Peter Sinclair, Thomas Craven Baddeley, Ahtsham Ishaq, Michael Simpson, Craig Williamson, Barry Alan Wood, Claude Michel Wischik, Charles Robert Harrington, Janet Elizabeth Rickard, David Horsley, Yin Sze Loh, Karrar Ahmad Khan, Christopher Paul Larch
-
Patent number: 10188658Abstract: Described are methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimized pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects.Type: GrantFiled: September 25, 2015Date of Patent: January 29, 2019Assignee: WisTa Laboratories Ltd.Inventors: Claude Michel Wischik, Damon Jude Wischik, John Mervyn David Storey, Charles Robert Harrington
-
Patent number: 9907804Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.Type: GrantFiled: February 29, 2016Date of Patent: March 6, 2018Assignee: WISTA LABORATORIES LTD.Inventors: Colin Marshall, Scott Clunas, John Mervyn David Storey, James Peter Sinclair, Thomas Craven Baddeley, Ahtsham Ishaq, Michael Simpson, Craig Williamson, Barry Alan Wood, Claude Michel Wischik, Charles Robert Harrington, Janet Elizabeth Rickard, David Horsley, Yin Sze Loh, Karrar Ahmad Khan, Christopher Paul Larch
-
Publication number: 20170088534Abstract: Described are a compound of formula (II) or (III): The compounds are effective in the treatment of disease, including a tauopathy condition or a disease of tau protein aggregation.Type: ApplicationFiled: December 8, 2016Publication date: March 30, 2017Applicant: WisTa Laboratories Ltd.Inventors: Scott CLUNAS, John Mervyn Davd STOREY, Janet Elizabeth RICKARD, David HORSLEY, Charles Robert HARRINGTON, Claude Michel WISCHIK
-
Patent number: 9549933Abstract: Described are a compound of formula (II) or (III): The compounds are effective in the treatment of disease, including a tauopathy condition or a disease of tau protein aggregation.Type: GrantFiled: February 14, 2014Date of Patent: January 24, 2017Assignee: WisTa Laboratories Ltd.Inventors: Scott Clunas, John Mervyn David Storey, Janet Elizabeth Rickard, David Horsley, Charles Robert Harrington, Claude Michel Wischik
-
Publication number: 20160237048Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.Type: ApplicationFiled: February 29, 2016Publication date: August 18, 2016Applicant: WisTa Laboratories Ltd.Inventors: COLIN MARSHALL, Scott Clunas, John Mervyn David Storey, James Peter Sinclair, Thomas Craven Baddeley, Ahtsham Ishaq, Michael Simpson, Craig Williamson, Barry Alan Wood, Claude Michel Wischik, Charles Robert Harrington, Janet Elizabeth Rickard, David Horsley, Yin Sze Loh, Karrar Ahmad Khan, Christopher Paul Larch